vs
ARBOR REALTY TRUST INC（ABR）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
ARBOR REALTY TRUST INC的季度营收约是RIGEL PHARMACEUTICALS INC的1.9倍（$133.4M vs $69.8M），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs -12.1%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs -8.9%）
Arbor Realty Trust Inc.是总部位于美国的专业房地产投资信托（REIT）企业，主要为多户住宅及商业地产项目提供结构性融资服务，涵盖过渡贷款、机构贷款、夹层融资等品类，服务覆盖美国各地的地产持有者、开发商及房产投资群体。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
ABR vs RIGL — 直观对比
营收规模更大
ABR
是对方的1.9倍
$69.8M
营收增速更快
RIGL
高出33.3%
-12.1%
两年增速更快
RIGL
近两年复合增速
-8.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $133.4M | $69.8M |
| 净利润 | — | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | — | 33.2% |
| 净利率 | — | 384.0% |
| 营收同比 | -12.1% | 21.2% |
| 净利润同比 | — | 1769.2% |
| 每股收益（稀释后） | $0.08 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABRRIGL
| Q4 25 | $133.4M | $69.8M | ||
| Q3 25 | $112.4M | $69.5M | ||
| Q2 25 | $130.4M | $101.7M | ||
| Q1 25 | $134.2M | $53.3M | ||
| Q4 24 | $151.7M | $57.6M | ||
| Q3 24 | $156.7M | $55.3M | ||
| Q2 24 | $153.1M | $36.8M | ||
| Q1 24 | $160.7M | $29.5M |
净利润ABRRIGL
| Q4 25 | — | $268.1M | ||
| Q3 25 | $52.0M | $27.9M | ||
| Q2 25 | $36.3M | $59.6M | ||
| Q1 25 | $43.4M | $11.4M | ||
| Q4 24 | — | $14.3M | ||
| Q3 24 | $73.5M | $12.4M | ||
| Q2 24 | $61.8M | $-1.0M | ||
| Q1 24 | $73.2M | $-8.2M |
毛利率ABRRIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率ABRRIGL
| Q4 25 | — | 33.2% | ||
| Q3 25 | — | 40.9% | ||
| Q2 25 | — | 60.1% | ||
| Q1 25 | — | 23.9% | ||
| Q4 24 | — | 28.9% | ||
| Q3 24 | — | 25.4% | ||
| Q2 24 | — | 1.2% | ||
| Q1 24 | 46.9% | -23.6% |
净利率ABRRIGL
| Q4 25 | — | 384.0% | ||
| Q3 25 | 46.3% | 40.2% | ||
| Q2 25 | 27.8% | 58.6% | ||
| Q1 25 | 32.3% | 21.5% | ||
| Q4 24 | — | 24.9% | ||
| Q3 24 | 46.9% | 22.5% | ||
| Q2 24 | 40.4% | -2.8% | ||
| Q1 24 | 45.6% | -27.9% |
每股收益（稀释后）ABRRIGL
| Q4 25 | $0.08 | $14.11 | ||
| Q3 25 | $0.20 | $1.46 | ||
| Q2 25 | $0.12 | $3.28 | ||
| Q1 25 | $0.16 | $0.63 | ||
| Q4 24 | $0.31 | $0.82 | ||
| Q3 24 | $0.31 | $0.70 | ||
| Q2 24 | $0.25 | $-0.06 | ||
| Q1 24 | $0.31 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $482.9M | $155.0M |
| 总债务越低越好 | $11.1B | $52.5M |
| 股东权益账面价值 | $3.0B | $391.5M |
| 总资产 | $14.5B | $513.6M |
| 负债/权益比越低杠杆越低 | 3.75× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资ABRRIGL
| Q4 25 | $482.9M | $155.0M | ||
| Q3 25 | $423.4M | $137.1M | ||
| Q2 25 | $255.7M | $108.4M | ||
| Q1 25 | $308.8M | $77.1M | ||
| Q4 24 | $503.8M | $77.3M | ||
| Q3 24 | $687.5M | $61.1M | ||
| Q2 24 | $737.5M | $49.1M | ||
| Q1 24 | $908.0M | $49.5M |
总债务ABRRIGL
| Q4 25 | $11.1B | $52.5M | ||
| Q3 25 | $10.4B | $60.0M | ||
| Q2 25 | $10.1B | $60.0M | ||
| Q1 25 | $9.9B | $60.0M | ||
| Q4 24 | $10.0B | $60.0M | ||
| Q3 24 | $10.3B | $60.0M | ||
| Q2 24 | $10.6B | $60.0M | ||
| Q1 24 | $11.4B | $60.0M |
股东权益ABRRIGL
| Q4 25 | $3.0B | $391.5M | ||
| Q3 25 | $3.0B | $117.6M | ||
| Q2 25 | $3.0B | $81.9M | ||
| Q1 25 | $3.0B | $18.6M | ||
| Q4 24 | $3.0B | $3.3M | ||
| Q3 24 | $3.0B | $-14.6M | ||
| Q2 24 | $3.1B | $-29.9M | ||
| Q1 24 | $3.1B | $-31.7M |
总资产ABRRIGL
| Q4 25 | $14.5B | $513.6M | ||
| Q3 25 | $13.9B | $242.5M | ||
| Q2 25 | $13.6B | $206.7M | ||
| Q1 25 | $13.4B | $176.0M | ||
| Q4 24 | $13.5B | $164.0M | ||
| Q3 24 | $13.9B | $139.4M | ||
| Q2 24 | $14.2B | $128.4M | ||
| Q1 24 | $15.1B | $126.5M |
负债/权益比ABRRIGL
| Q4 25 | 3.75× | 0.13× | ||
| Q3 25 | 3.47× | 0.51× | ||
| Q2 25 | 3.40× | 0.73× | ||
| Q1 25 | 3.29× | 3.23× | ||
| Q4 24 | 3.29× | 18.25× | ||
| Q3 24 | 3.40× | — | ||
| Q2 24 | 3.47× | — | ||
| Q1 24 | 3.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $372.4M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ABRRIGL
| Q4 25 | $372.4M | $22.0M | ||
| Q3 25 | $178.7M | $24.0M | ||
| Q2 25 | $60.0M | $30.5M | ||
| Q1 25 | $150.5M | $-893.0K | ||
| Q4 24 | $461.5M | $14.5M | ||
| Q3 24 | $85.0M | $21.7M | ||
| Q2 24 | $69.9M | $302.0K | ||
| Q1 24 | $260.0M | $-5.0M |
现金转化率ABRRIGL
| Q4 25 | — | 0.08× | ||
| Q3 25 | 3.44× | 0.86× | ||
| Q2 25 | 1.65× | 0.51× | ||
| Q1 25 | 3.47× | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | 1.16× | 1.75× | ||
| Q2 24 | 1.13× | — | ||
| Q1 24 | 3.55× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
